Gene info: ID 2067

Gene: ERCC1

GENE ID: 2067

Synonyms: COFS4|RAD10|UV20

Description: ERCC excision repair 1, endonuclease non-catalytic subunit

Gene type: protein-coding

Location: 19q13.32

dbXrefs: Ensembl:ENSG00000012061 MIM:126380 Vega:OTTHUMG00000182121 UniprotKB:P07992

RefSeq: NG_015839.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 69

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 7.739e-1 (AD) 5.666e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PREB	0.921
PSMB4	0.917
DDX56	0.916
STOML2	0.915
EIF3I	0.915
ARPC4	0.913
RAD23A	0.912
POLDIP2	0.91
EIF3B	0.91
PPM1G	0.906

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.812
OR4F29	-0.757
MTRNR2L6	-0.214
MTRNR2L9	-0.206
HMHB1	-0.198
OR6C74	-0.196
MTRNR2L10	-0.186
RNASE8	-0.173
VNN3	-0.173
C9orf153	-0.172

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ERCC1 mRNA"	26808241
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ERCC1 mRNA"	28712647
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of ERCC1 mRNA"	21346803
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of ERCC1 mRNA"	22100608
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	"2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of ERCC1 mRNA"	22100608
C026832	3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenz(a)anthracene	"3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenz(a)anthracene results in increased expression of ERCC1 mRNA"	22236718
C025160	3-aminobenzamide	3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
C025160	3-aminobenzamide	3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
C025160	3-aminobenzamide	3-aminobenzamide results in decreased expression of ERCC1 mRNA	22228707
C025160	3-aminobenzamide	3-aminobenzamide results in decreased expression of ERCC1 protein	22228707
C025160	3-aminobenzamide	3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]	22228707
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [resveratrol results in increased expression of ERCC1 mRNA]	23912706
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [resveratrol results in increased expression of ERCC1 protein]	23912706
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERCC1 mRNA"	27188386
C035207	4-amino-2,6-dinitrotoluene	"4-amino-2,6-dinitrotoluene affects the expression of ERCC1 mRNA"	21346803
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of ERCC1 mRNA	19191707
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERCC1 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen affects the expression of ERCC1 mRNA	17562736
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of ERCC1 mRNA	22100608
C059765	amphotericin B, deoxycholate drug combination	"amphotericin B, deoxycholate drug combination results in increased expression of ERCC1 mRNA"	22863853
D001151	Arsenic	Arsenic results in decreased expression of ERCC1 mRNA	12569548\|1688252
D001151	Arsenic	Arsenic results in decreased expression of ERCC1 protein	16882524
D001151	Arsenic	Arsenic results in increased expression of ERCC1 mRNA	19661343
D017636	Asbestos, Amphibole	"Asbestos, Amphibole results in increased expression of ERCC1 protein"	20855422
D001379	Azathioprine	Azathioprine results in increased expression of ERCC1 mRNA	22623647
C030935	benz(a)anthracene	benz(a)anthracene results in increased expression of ERCC1 mRNA	22236718
D001554	Benzene	Benzene affects the expression of ERCC1 mRNA	16188086
C043931	benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA	"ERCC1 gene polymorphism results in increased abundance of benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA"	23203453
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the expression of ERCC1 mRNA	20624995
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ERCC1 mRNA	21632981
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ERCC1 protein	19748547
D001564	Benzo(a)pyrene	ERCC1 protein affects the susceptibility to Benzo(a)pyrene	22382310
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ERCC1 mRNA	22228805\|2264161
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ERCC1 mRNA	21774909
D001564	Benzo(a)pyrene	ERCC1 protein affects the reaction [BRCA1 protein affects the susceptibility to Benzo(a)pyrene]	21507987
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of ERCC1 mRNA"	19150397
D004958	Estradiol	Estradiol results in decreased expression of ERCC1 mRNA	24349563
D004958	Estradiol	decitabine inhibits the reaction [Estradiol results in decreased expression of ERCC1 mRNA]	22082530
D004958	Estradiol	Estradiol results in decreased expression of ERCC1 mRNA	22082530
C006780	bisphenol A	bisphenol A results in increased expression of ERCC1 mRNA	25181051
D001761	Bleomycin	[ERCC4 protein binds to ERCC1 protein] which results in increased susceptibility to Bleomycin	22007867
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of ERCC1 mRNA	22112500\|2647268
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of ERCC1 protein	22112500
D019256	Cadmium Chloride	[Cadmium Chloride results in increased activity of [DNMT1 protein co-treated with DNMT3A protein]] which results in decreased expression of ERCC1 mRNA	22112500
D019256	Cadmium Chloride	[Cadmium Chloride results in increased activity of [DNMT1 protein co-treated with DNMT3A protein]] which results in increased methylation of ERCC1 promoter	22112500
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of ERCC1 protein	26220685
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of ERCC1 promoter	22112500
D019256	Cadmium Chloride	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of ERCC1 mRNA]	22112500
D019256	Cadmium Chloride	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of ERCC1 protein]	22112500
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of ERCC1 mRNA	15501611
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of ERCC1 mRNA	11958953
D019256	Cadmium Chloride	MT1 affects the reaction [Cadmium Chloride results in increased expression of ERCC1 mRNA]	11958953
D019256	Cadmium Chloride	MT2 affects the reaction [Cadmium Chloride results in increased expression of ERCC1 mRNA]	11958953
D002166	Camptothecin	Camptothecin results in decreased expression of ERCC1 mRNA	24792648
D002166	Camptothecin	ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AFX protein]]	21227924
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of ERCC1 mRNA	15056808
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ERCC1 gene	20938992
C530333	cis-diammine(pyridine)chloroplatinum(II)	cis-diammine(pyridine)chloroplatinum(II) results in decreased expression of ERCC1 mRNA	21750216
D003035	Cobalt	[Cobalt co-treated with Organometallic Compounds] results in increased expression of ERCC1 mRNA	22147119
D003035	Cobalt	Cobalt results in increased expression of ERCC1 mRNA	22147119
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of ERCC1 mRNA	19320972\|1937684
C018021	cobaltous chloride	cobaltous chloride results in increased expression of ERCC1 mRNA	24386269
D019327	Copper Sulfate	Copper Sulfate results in increased expression of ERCC1 mRNA	19549813
C029892	cupric chloride	cupric chloride results in increased expression of ERCC1 protein	22699969
D003474	Curcumin	Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
D003474	Curcumin	Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
D003474	Curcumin	Curcumin results in decreased expression of ERCC1 mRNA	17596214\|2149372
D003474	Curcumin	Curcumin results in decreased expression of ERCC1 protein	21493726\|2222870
D003474	Curcumin	[Curcumin results in decreased expression of ERCC1 protein] which results in increased susceptibility to Cisplatin	21493726
D003474	Curcumin	Curcumin inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]	22228707
D003520	Cyclophosphamide	Cyclophosphamide affects the expression of ERCC1 mRNA	11906922
D016572	Cyclosporine	Cyclosporine results in increased expression of ERCC1 mRNA	20106945
C093628	cyproconazole	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA	29038839
C014347	decitabine	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of ERCC1 mRNA]	22112500
C014347	decitabine	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of ERCC1 protein]	22112500
C014347	decitabine	decitabine inhibits the reaction [Estradiol results in decreased expression of ERCC1 mRNA]	22082530
C014347	decitabine	decitabine results in decreased expression of ERCC1 mRNA	22082530
D002945	Cisplatin	ERCC1 protein results in increased susceptibility to Cisplatin	21324906
D002945	Cisplatin	Cisplatin affects the expression of ERCC1 mRNA	21750216
D002945	Cisplatin	Cisplatin affects the expression of ERCC1 protein	24799992
D002945	Cisplatin	[Cisplatin co-treated with Fluorouracil] results in decreased expression of ERCC1 mRNA	15737843
D002945	Cisplatin	Cisplatin results in increased expression of ERCC1 mRNA	21165580\|2131508
D002945	Cisplatin	Cisplatin results in increased expression of ERCC1 protein	21315089\|2199673
D002945	Cisplatin	[Curcumin results in decreased expression of ERCC1 protein] which results in increased susceptibility to Cisplatin	21493726
D002945	Cisplatin	DUSP6 inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]	21996734
D002945	Cisplatin	ERCC1 gene polymorphism affects the susceptibility to [Cisplatin co-treated with S 1 (combination)]	21364592
D002945	Cisplatin	ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]	21264830
D002945	Cisplatin	ERCC1 gene SNP results in increased susceptibility to [Cisplatin co-treated with Fluorouracil]	21286668
D002945	Cisplatin	ERCC1 mRNA affects the susceptibility to [Cisplatin co-treated with Fluorouracil]	15173087
D002945	Cisplatin	ERCC1 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AFX protein]]]	21875941
D002945	Cisplatin	ERCC1 mutant form inhibits the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AFX protein]]	21875941
D002945	Cisplatin	ERCC1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin]]	21875941
D002945	Cisplatin	[ERCC1 protein binds to ERCC4 protein] which results in decreased susceptibility to Cisplatin	21357694
D002945	Cisplatin	ERCC1 protein results in decreased susceptibility to Cisplatin	21093896\|2131508
D002945	Cisplatin	ERCC1 protein results in increased susceptibility to Cisplatin	21076943
D002945	Cisplatin	ERCC1 results in decreased susceptibility to Cisplatin	21621119
D002945	Cisplatin	PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]	21996734
D002945	Cisplatin	PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]	21996734
D002945	Cisplatin	[sodium arsenite co-treated with Cisplatin] results in increased expression of ERCC1 protein	21696631
D002945	Cisplatin	ERCC1 results in decreased susceptibility to Cisplatin	21722328
D002945	Cisplatin	Cisplatin results in increased expression of ERCC1 mRNA	26739623
D002945	Cisplatin	Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA]	26739623
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate results in increased expression of ERCC1 mRNA	26924002
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA"	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	"[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	"epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	"[theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C024629	dimethyl phthalate	dimethyl phthalate results in increased expression of ERCC1 mRNA	26924002
D004317	Doxorubicin	Doxorubicin results in increased expression of ERCC1 mRNA	22712078
D004785	Environmental Pollutants	ERCC1 gene SNP affects the susceptibility to Environmental Pollutants	24036326
C045651	epigallocatechin gallate	"[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C045651	epigallocatechin gallate	"epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C109476	epoxiconazole	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA	29038839
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ERCC1 mRNA	17942748
D018120	Finasteride	Finasteride results in increased expression of ERCC1 mRNA	24136188
C007738	fluoranthene	[fluoranthene co-treated with Permethrin] results in increased expression of ERCC1 mRNA	22406618
D005472	Fluorouracil	[Cisplatin co-treated with Fluorouracil] results in decreased expression of ERCC1 mRNA	15737843
D005472	Fluorouracil	ERCC1 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with oxaliplatin]	15213713\|1844832
D005472	Fluorouracil	ERCC1 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
D005472	Fluorouracil	ERCC1 gene SNP results in increased susceptibility to [Cisplatin co-treated with Fluorouracil]	21286668
D005472	Fluorouracil	ERCC1 mRNA affects the susceptibility to [Cisplatin co-treated with Fluorouracil]	15173087
D005472	Fluorouracil	Fluorouracil results in decreased expression of ERCC1 mRNA	17016597
D005485	Flutamide	Flutamide results in increased expression of ERCC1 mRNA	24136188
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ERCC1 gene	20938992
D004397	Fonofos	ERCC1 polymorphism affects the susceptibility to Fonofos	22102698
D005557	Formaldehyde	ERCC1 gene mutant form results in increased susceptibility to Formaldehyde	22186232
D002955	Leucovorin	ERCC1 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
C039281	furan	furan results in increased expression of ERCC1 mRNA	22079235
C419708	gefitinib	ERCC1 gene polymorphism affects the susceptibility to gefitinib	21264830
C419708	gefitinib	ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]	21264830
D005947	Glucose	3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
D005947	Glucose	3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
D005947	Glucose	Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
D005947	Glucose	Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
D005947	Glucose	ERCC1 protein affects the reaction [Glucose results in increased expression of EP300 mRNA]	22228707
D005947	Glucose	ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 mRNA]	22228707
D005947	Glucose	ERCC1 protein affects the reaction [Glucose results in increased expression of ERCC4 protein]	22228707
D005947	Glucose	ERCC1 protein affects the reaction [Glucose results in increased expression of FN1 mRNA]	22228707
D005947	Glucose	ERCC1 protein affects the reaction [Glucose results in increased expression of PARP1 mRNA]	22228707
D005947	Glucose	ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
D005947	Glucose	ERCC4 protein affects the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
D005947	Glucose	Glucose results in increased expression of ERCC1 mRNA	22228707
D005947	Glucose	Glucose results in increased expression of ERCC1 protein	22228707
D005947	Glucose	trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
D005947	Glucose	trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
D017313	Fenretinide	Fenretinide results in increased expression of ERCC1 protein	15059897
D017313	Fenretinide	Fenretinide results in increased expression of ERCC1 mRNA	28973697
D006861	Hydrogen Peroxide	ERCC1 protein affects the susceptibility to Hydrogen Peroxide	22007867
D006861	Hydrogen Peroxide	[ERCC4 protein binds to ERCC1 protein] which results in increased susceptibility to Hydrogen Peroxide	22007867
C051890	irinotecan	irinotecan results in decreased expression of ERCC1 protein	11593056
C017461	lead nitrate	lead nitrate affects the reaction [ERCC1 affects the expression of MT1 mRNA]	11891201
C017461	lead nitrate	lead nitrate affects the reaction [ERCC1 affects the expression of MT2 mRNA]	11891201
D001556	Lindane	Lindane results in increased expression of ERCC1 mRNA	24349563
D008070	Lipopolysaccharides	[usnic acid co-treated with Lipopolysaccharides] results in decreased expression of ERCC1 mRNA	22777745
D018021	Lithium Chloride	Lithium Chloride results in increased expression of ERCC1 mRNA	15711924
D008148	Lovastatin	Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA]	26739623
D008148	Lovastatin	Lovastatin results in increased expression of ERCC1 mRNA	26739623
D008550	Melatonin	Melatonin results in increased expression of ERCC1 protein	24799992
D058955	Metalloids	ERCC1 gene SNP affects the susceptibility to Metalloids	24036326
D008670	Metals	ERCC1 gene SNP affects the susceptibility to Metals	24036326
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ERCC1 gene	20938992
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of ERCC1 mRNA	20375079
C008493	methylselenic acid	methylselenic acid results in increased expression of ERCC1 mRNA	12517777
C063855	microcystin RR	microcystin RR results in decreased expression of ERCC1 protein	19111056
C517284	monomethyl phthalate	monomethyl phthalate results in increased expression of ERCC1 mRNA	26924002
C005246	myristicin	myristicin results in decreased expression of ERCC1 mRNA	24792648
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of ERCC1 mRNA"	25554681
C484027	oligofectamine	oligofectamine results in increased expression of ERCC1 mRNA	14668052
D009942	Organometallic Compounds	[Cobalt co-treated with Organometallic Compounds] results in increased expression of ERCC1 mRNA	22147119
C030110	oxaliplatin	ERCC1 gene polymorphism affects the susceptibility to [Fluorouracil co-treated with oxaliplatin]	15213713\|1844832
C030110	oxaliplatin	ERCC1 gene polymorphism affects the susceptibility to oxaliplatin	20979931
C030110	oxaliplatin	ERCC1 gene SNP affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]	17401013
C030110	oxaliplatin	ERCC1 protein affects the susceptibility to oxaliplatin	15041737\|1565554
C030110	oxaliplatin	oxaliplatin results in increased expression of ERCC1 mRNA	16773204
D010269	Paraquat	[ERCC4 protein binds to ERCC1 protein] which results in increased susceptibility to Paraquat	22007867
D010269	Paraquat	Paraquat affects the splicing of ERCC1 mRNA	23613995
D052638	Particulate Matter	Particulate Matter affects the expression of ERCC1 mRNA	12919963
D052638	Particulate Matter	Particulate Matter results in increased expression of ERCC1 mRNA	12937889
C506614	PD 0325901	PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]	21996734
C506614	PD 0325901	PD 0325901 inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]	21996734
C506614	PD 0325901	PD 0325901 results in decreased expression of ERCC1 mRNA	21996734
D000068437	Pemetrexed	Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]	23912706
D000068437	Pemetrexed	Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]	23912706
D000068437	Pemetrexed	Pemetrexed results in decreased expression of ERCC1 mRNA	23912706
D000068437	Pemetrexed	Pemetrexed results in decreased expression of ERCC1 protein	23912706
D000068437	Pemetrexed	MAP2K6 protein mutant form inhibits the reaction [Pemetrexed inhibits the reaction [resveratrol results in increased expression of ERCC1 protein]]	23912706
D026023	Permethrin	[fluoranthene co-treated with Permethrin] results in increased expression of ERCC1 mRNA	22406618
D026023	Permethrin	Permethrin results in decreased expression of ERCC1 mRNA	22406618
D026023	Permethrin	Permethrin results in increased expression of ERCC1 mRNA	22406618
D010862	Pilocarpine	Pilocarpine results in increased expression of ERCC1 mRNA	17971868
C049032	pinosylvin	pinosylvin results in increased expression of ERCC1 mRNA	23333577
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ERCC1 mRNA	19710929
D010984	Platinum	ERCC1 protein affects the susceptibility to Platinum	15788669
C043435	polylactic acid-polyglycolic acid copolymer	"[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C043435	polylactic acid-polyglycolic acid copolymer	"[theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C045362	prochloraz	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA	29038839
C031280	pyrazole	pyrazole results in increased expression of ERCC1 mRNA	17945193
D011794	Quercetin	Quercetin results in increased expression of ERCC1 mRNA	21632981
C012526	quercitrin	quercitrin results in decreased expression of ERCC1 mRNA	25193878
D017382	Reactive Oxygen Species	[ERCC4 protein binds to ERCC1 protein] which results in decreased activity of Reactive Oxygen Species	22007867
C059514	resveratrol	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [resveratrol results in increased expression of ERCC1 mRNA]	23912706
C059514	resveratrol	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [resveratrol results in increased expression of ERCC1 protein]	23912706
C059514	resveratrol	ERCC1 protein affects the susceptibility to resveratrol	23912706
C059514	resveratrol	Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]	23912706
C059514	resveratrol	Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]	23912706
C059514	resveratrol	resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA	23912706
C059514	resveratrol	resveratrol results in increased stability of and results in increased expression of ERCC1 protein	23912706
C059514	resveratrol	MAP2K6 protein mutant form inhibits the reaction [Pemetrexed inhibits the reaction [resveratrol results in increased expression of ERCC1 protein]]	23912706
D015474	Isotretinoin	Isotretinoin results in decreased expression of ERCC1 mRNA	20436886
C547185	riccardin D	riccardin D results in decreased expression of ERCC1 mRNA	24069304
C079198	S 1 (combination)	ERCC1 gene polymorphism affects the susceptibility to [Cisplatin co-treated with S 1 (combination)]	21364592
C093642	SB 203580	SB 203580 inhibits the reaction [tanshinone results in decreased expression of ERCC1 mRNA]	21165580
C093642	SB 203580	SB 203580 results in increased expression of ERCC1 mRNA	21165580
D012643	Selenium	Selenium results in increased expression of ERCC1 mRNA	19244175
C009277	sodium arsenate	sodium arsenate results in increased expression of ERCC1 mRNA	11353140
C017947	sodium arsenite	[sodium arsenite co-treated with Cisplatin] results in increased expression of ERCC1 protein	21696631
C017947	sodium arsenite	sodium arsenite results in decreased expression of ERCC1 mRNA	21776218
C017947	sodium arsenite	sodium arsenite results in increased expression of ERCC1 mRNA	11353140
C016104	sodium bichromate	sodium bichromate results in decreased expression of ERCC1 mRNA	17685462
D018038	Sodium Selenite	Sodium Selenite results in increased expression of ERCC1 mRNA	18175754
D013311	Streptozocin	3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]	22228707
D013311	Streptozocin	Curcumin inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]	22228707
D013311	Streptozocin	Streptozocin results in increased expression of ERCC1 mRNA	22228707
D013311	Streptozocin	Streptozocin results in increased expression of ERCC1 protein	22228707
C021751	tanshinone	SB 203580 inhibits the reaction [tanshinone results in decreased expression of ERCC1 mRNA]	21165580
C021751	tanshinone	tanshinone results in decreased expression of ERCC1 mRNA	21165580
C020806	tetrabromobisphenol A	tetrabromobisphenol A results in increased expression of ERCC1 mRNA	25172293
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ERCC1 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ERCC1 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERCC1 promoter]	19654925
C056068	theaflavin	"[theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]"	23717041
C012589	trichostatin A	trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]	22228707
C012589	trichostatin A	trichostatin A inhibits the reaction [Glucose results in increased expression of ERCC1 protein]	22228707
C012589	trichostatin A	trichostatin A results in decreased expression of ERCC1 mRNA	22228707
C012589	trichostatin A	trichostatin A results in decreased expression of ERCC1 protein	22228707
C073339	usnic acid	[usnic acid co-treated with Lipopolysaccharides] results in decreased expression of ERCC1 mRNA	22777745
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERCC1 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of ERCC1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of ERCC1 mRNA	26272509
D014635	Valproic Acid	Valproic Acid affects the expression of ERCC1 mRNA	17292431
D014640	Vancomycin	Vancomycin results in decreased expression of ERCC1 mRNA	18930951
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of ERCC1 gene	25560391
D001335	Vehicle Emissions	Vehicle Emissions affects the expression of ERCC1 mRNA	12919963
D001335	Vehicle Emissions	Vehicle Emissions results in increased expression of ERCC1 mRNA	12937889
C521013	veliparib	ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AFX protein]]	21227924
C025643	vinclozolin	vinclozolin results in decreased expression of ERCC1 mRNA	23034163
D014810	Vitamin E	Vitamin E results in increased expression of ERCC1 mRNA	19244175
C108830	Y 27632	Y 27632 results in increased expression of ERCC1 mRNA	20878077
D015032	Zinc	Zinc results in increased expression of ERCC1 mRNA	15226459
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of ERCC1 mRNA	15226459

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000014	single-stranded DNA endodeoxyribonuclease activity	-	IBA	21873635
GO:0000014	single-stranded DNA endodeoxyribonuclease activity	contributes_to	IDA	7559382
GO:0001094	TFIID-class transcription factor binding	-	IEA	-
GO:0003677	DNA binding	contributes_to	IDA	14734547
GO:0003684	damaged DNA binding	-	IBA	21873635
GO:0003684	damaged DNA binding	-	IDA	17720715
GO:0003697	single-stranded DNA binding	-	IBA	21873635
GO:0003697	single-stranded DNA binding	-	IDA	16076955 17720715
GO:0005515	protein binding	-	IPI	7559382 8197175 9013642 11058119 14690602 14706347 16189514 16338413 16491090 16756962 17055345 17289582 18812185 19596235 19596236 24780295 25416956
GO:0008022	protein C-terminus binding	-	IPI	9722633
GO:0019904	protein domain specific binding	-	IPI	17720715
GO:1990599	3' overhang single-stranded DNA endodeoxyribonuclease activity	contributes_to	IMP	14690602

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000710	meiotic mismatch repair	-	IBA	21873635
GO:0000720	pyrimidine dimer repair by nucleotide-excision repair	-	IEA	-
GO:0001302	replicative cell aging	-	IEA	-
GO:0006281	DNA repair	-	IMP	25538220
GO:0006283	transcription-coupled nucleotide-excision repair	-	TAS	-
GO:0006289	nucleotide-excision repair	-	IDA	3290851
GO:0006289	nucleotide-excision repair	-	IGI	11707424
GO:0006293	nucleotide-excision repair, preincision complex stabilization	-	TAS	-
GO:0006295	nucleotide-excision repair, DNA incision, 3'-to lesion	-	IMP	7657672
GO:0006296	nucleotide-excision repair, DNA incision, 5'-to lesion	-	IBA	21873635
GO:0006296	nucleotide-excision repair, DNA incision, 5'-to lesion	-	IMP	7657672
GO:0006296	nucleotide-excision repair, DNA incision, 5'-to lesion	-	TAS	-
GO:0006303	double-strand break repair via nonhomologous end joining	-	IMP	14690602
GO:0006310	DNA recombination	-	IGI	11707424
GO:0006312	mitotic recombination	-	IBA	21873635
GO:0006312	mitotic recombination	-	IMP	8811092
GO:0006949	syncytium formation	-	IEA	-
GO:0006979	response to oxidative stress	-	IMP	9256505 17614221
GO:0007283	spermatogenesis	-	IEA	-
GO:0007584	response to nutrient	-	IEA	-
GO:0008283	cell proliferation	-	IEA	-
GO:0008584	male gonad development	-	IEA	-
GO:0009650	UV protection	-	IEA	-
GO:0009744	response to sucrose	-	IEA	-
GO:0010165	response to X-ray	-	IEA	-
GO:0010259	multicellular organism aging	-	IEA	-
GO:0032205	negative regulation of telomere maintenance	-	IMP	17055345
GO:0033683	nucleotide-excision repair, DNA incision	-	TAS	-
GO:0035166	post-embryonic hemopoiesis	-	IEA	-
GO:0035264	multicellular organism growth	-	IEA	-
GO:0035902	response to immobilization stress	-	IEA	-
GO:0036297	interstrand cross-link repair	-	TAS	-
GO:0045190	isotype switching	-	IEA	-
GO:0046686	response to cadmium ion	-	IEA	-
GO:0048477	oogenesis	-	IEA	-
GO:0048568	embryonic organ development	-	IEA	-
GO:0061819	telomeric DNA-containing double minutes formation	-	IMP	14690602
GO:0070911	global genome nucleotide-excision repair	-	TAS	-
GO:0070914	UV-damage excision repair	-	IBA	21873635
GO:0090656	t-circle formation	-	ISS	-
GO:1904431	positive regulation of t-circle formation	-	ISS	-
GO:1905765	negative regulation of protection from non-homologous end joining at telomere	-	IMP	14690602

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000109	nucleotide-excision repair complex	-	IDA	3290851 7559382 8197175
GO:0000110	nucleotide-excision repair factor 1 complex	-	IBA	21873635
GO:0000110	nucleotide-excision repair factor 1 complex	-	IDA	10413517
GO:0000784	nuclear chromosome, telomeric region	-	IDA	14690602
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005669	transcription factor TFIID complex	-	IEA	-
GO:0005829	cytosol	-	IDA	-
GO:0070522	ERCC4-ERCC1 complex	-	IBA	21873635
GO:0070522	ERCC4-ERCC1 complex	-	IDA	14690602 17055345

KEGG ID	KEGG Term
hsa03420	Nucleotide excision repair

Reactome ID	Reactome Term	Evidence
R-HSA-5685938	HDR through Single Strand Annealing (SSA)	TAS
R-HSA-5693532	DNA Double-Strand Break Repair	TAS
R-HSA-5693538	Homology Directed Repair	TAS
R-HSA-5693567	HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)	TAS
R-HSA-5696395	Formation of Incision Complex in GG-NER	TAS
R-HSA-5696398	Nucleotide Excision Repair	TAS
R-HSA-5696399	Global Genome Nucleotide Excision Repair (GG-NER)	TAS
R-HSA-5696400	Dual Incision in GG-NER	TAS
R-HSA-6781827	Transcription-Coupled Nucleotide Excision Repair (TC-NER)	TAS
R-HSA-6782135	Dual incision in TC-NER	TAS
R-HSA-6783310	Fanconi Anemia Pathway	TAS
R-HSA-73894	DNA Repair	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
23889225	Inter-individual variation of smoking-related DNA adducts in lymphocytes-relationship to mRNA levels for CYP1A1 and DNA repair enzymes. (2000)	Ichiba M	Biomarkers
29172271	Association between ERCC1 Polymorphism and the Risk and Clinicopathological Features of Breast Cancer in Thai Women in the Lower Northeastern Region (2017 Nov 26)	Pongsavee M	Asian Pac J Cancer Prev
24935625	Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. (2014 Jul)	Sad LM	Med Oncol
18451256	Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. (2008 May 1)	Yu D	Clin Cancer Res
21327329	Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. (2011 May)	Lai TC	Oncol Rep
27668351	Study of association between pre-senile cataracts and rs11615 of ERCC1, rs13181 of ERCC2, and rs25487 of XRCC1 polymorphisms in a Spanish population. (2017 Jul-Aug)	Lopez-Valverde G	Ophthalmic Genet
22938424	Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. (2012)	Zhang ZY	Asian Pac J Cancer Prev
27183913	Fine-mapping markers of lung cancer susceptibility in a sub-region of chromosome 19q13.3 among Chinese. (2016 Sep 20)	Yin J	Oncotarget
23336484	[Epithelial growth factor receptor mutation status to the effective of survival in non-small cell lung cancer after surgery]. (2012 Dec)	Liu Y	Zhonghua Wai Ke Za Zhi
24563277	Association of single nucleotide polymorphisms of nucleotide excision repair genes with laryngeal cancer risk and interaction with cigarette smoking and alcohol drinking. (2014 May)	Li X	Tumour Biol
25025378	ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma. (2014)	Jin H	PLoS One
22335888	A specific diplotype defined by PPP1R13L rs1970764, CD3EAP rs967591 and ERCC1 rs11615 and lung cancer risk in a Chinese population. (2012 Jun)	Yin J	Lung Cancer
22002622	Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis. (2012 Jan)	Zhang L	Mutagenesis
25194563	Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. (2015 Apr)	Podmaniczky E	Pathol Oncol Res
24140460	HapMap-based study identifies risk sub-region on chromosome 19q13.3 in relation to lung cancer among Chinese. (2013 Dec)	Yin J	Cancer Epidemiol
23846458	ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. (2013 Oct)	Patel MR	Otolaryngol Head Neck Surg
16308313	DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. (2006 May)	Matullo G	Carcinogenesis
19444904	Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. (2009 Sep 15)	Abbasi R	Int J Cancer
15734977	Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. (2005 Feb)	Zhou W	Cancer Epidemiol Biomarkers Prev
22093627	[EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer]. (2011 Jul)	Deng QH	Zhonghua Zhong Liu Za Zhi
16103444	Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. (2005 Aug)	Wei Q	Cancer Epidemiol Biomarkers Prev
21875468	[Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer]. (2011 May)	Ma W	Zhonghua Zhong Liu Za Zhi
24582975	Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA. (2014 May 25)	Lu B	Gene
20973062	Accelerated aging of intervertebral discs in a mouse model of progeria. (2010 Dec)	Vo N	J Orthop Res
16284380	Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. (2005 Nov)	Matullo G	Cancer Epidemiol Biomarkers Prev
19297315	The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. (2009 Jul)	Planchard D	Ann Oncol
16537713	Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. (2006 Mar)	Garcia-Closas M	Cancer Epidemiol Biomarkers Prev
22740911	Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. (2012 Feb)	Zhang L	Oncol Lett
16690207	Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. (2007 Mar 8)	Vogel U	Cancer Lett
21216194	DNA repair gene polymorphisms and micronucleus frequencies in Chinese workers exposed to vinyl chloride monomer. (2011 Jun)	Qiu YL	Int J Hyg Environ Health
16806437	Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association. (2006 Dec)	Weiss JM	Gynecol Oncol
24211096	Investigating the role of DNA damage in tobacco smoking-induced spine degeneration. (2014 Mar 1)	Nasto LA	Spine J
23086647	[Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer]. (2012 Sep)	Zhang GB	Zhejiang Da Xue Xue Bao Yi Xue Ban
11900225	Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. (2002 Jan 15)	Cheng L	Cancer
20863778	Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. (2011 Apr)	Jones NR	Cancer Epidemiol
26617899	Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. (2015)	Sun Y	Int J Clin Exp Pathol
18026184	NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. (2008)	Hooker S	Prostate Cancer Prostatic Dis
24933103	Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. (2014)	Du Y	PLoS One
21942242	Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status. (2012 Apr)	Kim HN	Leuk Lymphoma
10910954	Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. (2000 Aug)	Cheng L	Carcinogenesis
16679872	Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. (2006 Jun)	Yang M	Eur J Cancer Prev
23435956	Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix. (2013 May)	Bajpai D	Mol Cell Biochem
22044695	Genetic variants associated with the risk of chronic obstructive pulmonary disease with and without lung cancer. (2012 Mar)	de Andrade M	Cancer Prev Res (Phila)
16364765	Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. (2006 Jan 1)	Yin J	Cancer Genet Cytogenet
26681190	Genetic Polymorphisms in XRCC1, CD3EAP, PPP1R13L, XPB, XPC, and XPF and the Risk of Chronic Benzene Poisoning in a Chinese Occupational Population. (2015)	Xue P	PLoS One
21426588	High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. (2011 Mar 23)	Chiu TJ	J Transl Med
21601580	HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population. (2011 Aug 1)	Yin J	Mutat Res
24667263	[Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study]. (2014 Mar)	Yang X	Zhongguo Fei Ai Za Zhi
24841208	Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis. (2014)	Zhu J	PLoS One
28464886	A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells. (2017 May 2)	Yeo J	BMC Cancer
23147699	Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population. (2013 Feb 18)	Xiao S	Mutat Res
24994038	Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. (2014 Dec)	Deng LL	J Cancer Res Clin Oncol
17303907	Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. (2006)	Park SY	Med Oncol
22415779	p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. (2012 Oct 15)	Planchard D	Cancer
20731898	[Relationship between polymorphisms of DNA repair gene ERCC1 and susceptibility to lung cancer.]. (2008 Apr 20)	Zhang Z	Zhongguo Fei Ai Za Zhi
18386788	Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. (2008 Jul 1)	Doecke J	Int J Cancer
25667646	Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. (2015 Mar)	Xu CW	Exp Ther Med
18289367	A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. (2008 Feb 20)	Hansen RD	BMC Cancer
18615480	Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. (2009 Mar)	Yang ZH	Mol Carcinog
20003463	Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. (2009 Dec 15)	Yin Z	BMC Cancer
26033827	Genetic variation affects congenital heart defect susceptibility in offspring exposed to maternal tobacco use. (2015 Oct)	Tang X	Birth Defects Res A Clin Mol Teratol
18544627	Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. (2008 Jun 15)	McWilliams RR	Cancer Res
16393248	Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. (2006 Jan)	Sugimura T	J Oral Pathol Med
20003391	ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. (2009 Dec 14)	Yin Z	J Exp Clin Cancer Res
19337508	Elevated human telomerase reverse transcriptase gene expression in blood cells associated with chronic arsenic exposure in Inner Mongolia, China. (2009 Mar)	Mo J	Environ Health Perspect
24313652	Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. (2014 Feb)	Weiss J	Expert Rev Anticancer Ther
26542178	Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer. (2016 Aug)	Lafuente-Sanchis A	Clin Transl Oncol
17489733	Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. (2007 May)	Felip E	Expert Rev Mol Diagn
29581776	Association of Smoking and XPG, CYP1A1, OGG1, ERCC5, ERCC1, MMP2, and MMP9 Gene Polymorphisms with the early detection and occurrence of Laryngeal Squamous Carcinoma. (2018)	Zhu Y	J Cancer